
Novartis aims to solve EpiPen shortage with generic launch of Symjepi to US pharmacies
pharmafile | July 10, 2019 | News story | Manufacturing and Production, Research and Development, Sales and Marketing | Mylan, Novartis, Sandoz, US, epipen, pharma
Novartis has announced the immediate availability of its generic epinephrine auto-injector in pharmacies throughout the US, as it moves to remedy the nation’s shortage of the potentially life-saving drug.
The shortage, which has now gone on for an entire year, hinges on the availability of Mylan’s EpiPen, the most common and well-known version of the drug, in what the FDA has characterised as “manufacturing delays”. The problem, according to Mylan, lies at the feet of Meridian Medical Technologies, a Pfizer subsidiary that manufactures the devices.
In response to the ongoing shortage, Novartis’ Sandoz unit made its Symjepi auto-injector available to hospitals in January, but now is extending that availability to pharmacies, as part of a commercialisation agreement with Adamis Pharmaceuticals Corp. The price for a two-pack is $250 – $50 cheaper than Mylan’s own generic version of its flagship product.
According to Pfizer, the ongoing shortage should be expected to continue over the coming months.
Matt Fellows
Related Content

Pharma sees climate disruption as growing supply-chain risk
Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …

AI in pharma: From lab development to patient impact
In the decade to 2025, AI use in vaccine development has increased markedly but is …

Cell therapy partnership aims to bring liver disease treatment closer to US patients
Resolution Therapeutics has partnered with the Blood Centers of America (BCA) to support community-based delivery …





